Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

$EPIX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $EPIX alert in real time by email
SC 13G/A 1 d854164dsc13ga.htm SC 13G/A SC 13G/A

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 5)*

 

 

ESSA Pharma Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

29668H708

(CUSIP Number)

November 1, 2024

(Date of Event Which Requires Filing This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

 

Rule 13d-1(b)

 

 

Rule 13d-1(c)

 

 

Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 29668H708

 

 1.   

 Names of Reporting Persons

 

 BB Biotech AG

 2.  

 Check the Appropriate Box if a Member of a Group (See Instructions)

 

 (a) ☒  (b) ☐

 3.  

 SEC Use Only

 

 4.  

  Citizenship or Place of Organization

 

 Switzerland

Number of

Shares Beneficially 

Owned by

Each

Reporting

Person

with:

   5.   

 Sole Voting Power

 

 0

   6.  

 Shared Voting Power

 

 0

   7.  

 Sole Dispositive Power

 

 0

   8.  

 Shared Dispositive Power

 

 0

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 0

10.  

 Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented by amount in Row (9)

 

 0.0%

12.  

 Type of Reporting Person (See Instructions)

 

 HC, CO

 

2 of 6


CUSIP No. 29668H708

 

 1.   

 Names of Reporting Persons

 

 Biotech Growth N.V.

 

 I.R.S. Identification Nos. of above persons (entities only):

 

 N/A

 2.  

 Check the Appropriate Box if a Member of a Group (See Instructions)

 

 (a) ☒  (b) ☐

 3.  

 SEC Use Only

 

 4.  

  Citizenship or Place of Organization

 

 Curacao

Number of

Shares Beneficially 

Owned by

Each

Reporting

Person

with:

   5.   

 Sole Voting Power

 

 0

   6.  

 Shared Voting Power

 

 0

   7.  

 Sole Dispositive Power

 

 0

   8.  

 Shared Dispositive Power

 

 0

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 0

10.  

 Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented by amount in Row (9)

 

 0.0%

12.  

 Type of Reporting Person (See Instructions)

 

 CO

 

3 of 6


Item 1

1(a) Name of Issuer: ESSA Pharma Inc.

1(b) Address of Issuer’s Principal Executive Offices:

Suite 720, 999 West Broadway, Vancouver, British Columbia V5Z 1K5, Canada

Item 2

2(a) Name of Person Filing: BB Biotech AG (“BB Biotech”) on behalf of its wholly-owned subsidiary, Biotech Growth N.V. (“Biotech Growth”)

2(b) Address of Principal Business Office or, if none, Residence:

BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland

Biotech Growth N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao

2(c) Citizenship: BB Biotech AG: Switzerland

Biotech Growth N.V.: Curacao

2(d) Title of Class of Securities Common Shares, no par value

2(e) CUSIP Number 29668H708

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a)

Amount beneficially owned: 0

 

  (b)

Percent of class: 0.0%

 

  (c)

Number of shares as to which the person has:

 

  (i)

Sole power to vote or to direct the vote 0

 

  (ii)

Shared power to vote or to direct the vote 0

 

  (iii)

Sole power to dispose or to direct the disposition of 0

 

  (iv)

Shared power to dispose or to direct the disposition of 0

Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following .

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

This statement is filed jointly by BB Biotech and Biotech Growth, Biotech Growth is a wholly-owned subsidiary of BB Biotech.

 

4 of 6


Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

BB Biotech AG      
Date: November 13, 2024     By:  

/s/ Martin Gubler

      Signatory Authority
    Name:   Martin Gubler
    Title:   Signatory Authority
Date: November 13, 2024     By:  

/s/ Ivo Betschart

      Signatory Authority
    Name:   Ivo Betschart
    Title:   Signatory Authority
Biotech Growth N.V.      
Date: November 13, 2024     By:  

/s/ Jan Bootsma

      Signatory Authority
    Name:   Jan Bootsma
    Title:   Signatory Authority
Date: November 13, 2024     By:  

/s/ Hugo van Neutegem

      Signatory Authority
    Name:   Hugo van Neutegem
    Title:   Signatory Authority

 

5 of 6


Exhibit Index

Exhibit A: Agreement by and between BB Biotech AG and Biotech Growth N.V. with respect to the filing of this disclosure statement.*

 

*

Previously filed as an exhibit to BB Biotech AG and Biotech Growth N.V.’s Schedule 13G filed with the Securities and Exchange Commission on May 5, 2021.

 

6 of 6

Get the next $EPIX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EPIX

DatePrice TargetRatingAnalyst
11/4/2024Buy → Hold
Jefferies
11/4/2024Outperform → Perform
Oppenheimer
11/4/2024$15.00 → $2.00Overweight → Neutral
Piper Sandler
6/26/2023$17.00Outperform
Oppenheimer
8/17/2021$36.00 → $22.00Outperform
Oppenheimer
More analyst ratings

$EPIX
Press Releases

Fastest customizable press release news feed in the world

See more
  • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

    SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot

    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024

    Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 11, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal first quarter ended December 31, 2024. "Following our decision to terminate the clinical development of masofaniten, we have been evaluating and reviewing strategic options with a focus on maximizing shareholder valu

    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024

    Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 17, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2024. "We recently made the difficult decision to terminate the clinical development of m

    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EPIX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$EPIX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$EPIX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$EPIX
SEC Filings

See more

$EPIX
Leadership Updates

Live Leadership Updates

See more
  • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

    SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot

    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

    SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berg

    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

    SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin

    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EPIX
Financials

Live finance-specific insights

See more
  • ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024

    Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 11, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal first quarter ended December 31, 2024. "Following our decision to terminate the clinical development of masofaniten, we have been evaluating and reviewing strategic options with a focus on maximizing shareholder valu

    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024

    Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 17, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2024. "We recently made the difficult decision to terminate the clinical development of m

    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024

    On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in the first quarter of 2025, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations well beyond 2025 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 5, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the

    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EPIX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more